Evaluating the Use of Glucocorticoids Among Belimumab‐Treated Patients With Systemic Lupus Erythematosus in Real‐World Settings Using the Rheumatology Informatics System for Effectiveness Registry

Glucocorticoids are part of standard therapy for systemic lupus erythematosus (SLE), despite adverse effects associated with long‐term treatment. Belimumab improved clinical manifestations of SLE and reduced glucocorticoid doses in clinical trials and clinical practice; however, associations have not been examined using multi‐institutional electronic health record (EHR) data. Using the Rheumatology Informatics System for Effectiveness registry, we examined glucocorticoid use patterns among belimumab‐treated adults with SLE.

[1]  J. Birt,et al.  Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis , 2020, Lupus science & medicine.

[2]  A. Schwarting,et al.  Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies , 2020, Rheumatology and Therapy.

[3]  J. Yazdany,et al.  Quality of Care for Patients With Systemic Lupus Erythematosus: Data From the American College of Rheumatology RISE Registry , 2020, Arthritis care & research.

[4]  A. Gabrielli,et al.  Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting , 2020, Arthritis & rheumatology.

[5]  H. Kan,et al.  Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA , 2020, Lupus Science & Medicine.

[6]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.

[7]  M. Infantino,et al.  European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view , 2019, Annals of the Rheumatic Diseases.

[8]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.

[9]  C. Gordon,et al.  2019 update of the EULAR recommendations for the management of systemic lupus erythematosus , 2019, Annals of the rheumatic diseases.

[10]  K. Liao,et al.  Rheumatology Informatics System for Effectiveness: A National Informatics‐Enabled Registry for Quality Improvement , 2016, Arthritis care & research.

[11]  M. Petri,et al.  Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials , 2016, Arthritis & rheumatology.

[12]  M. Dall'era,et al.  Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA , 2016, Lupus Science & Medicine.

[13]  H. Kan,et al.  A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings. , 2015, Clinical therapeutics.

[14]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[15]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[16]  L. Trupin,et al.  Hydroxychloroquine treatment in a community‐based cohort of patients with systemic lupus erythematosus , 2010, Arthritis care & research.

[17]  D. Gladman,et al.  Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. , 1999, Arthritis and rheumatism.